Patents by Inventor Gregory L. Moore

Gregory L. Moore has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Heterodimeric human IgG1 polypeptides with isoelectric point modifications
    Patent number: 12662553
    Abstract: The invention relates generally to compositions and methods for purifying the desired species from a mixture of desired heterodimer and contaminating homodimer immunoglobulin variants by modifying the isoelectric point(s) of the individual chains.
    Type: Grant
    Filed: October 1, 2025
    Date of Patent: June 23, 2026
    Assignee: Xencor, Inc.
    Inventors: Gregory L. Moore, Gregory Lazar
  • METHODS AND COMPOSITIONS FOR INHIBITING CD32B EXPRESSING CELLS
    Publication number: 20260159590
    Abstract: The present disclosure relates to immunoglobulins that bind Fc?RIIb+ cells and coengage the antigen on the cell's surface and an Fc?RIIb on the cell's surface, methods for their generation, and methods for using the immunoglobulins.
    Type: Application
    Filed: February 4, 2026
    Publication date: June 11, 2026
    Inventors: Seung Yup Chu, John R. Desjarlais, Sher Bahadur Karki, Gregory Alan Lazar, Gregory L. Moore, Igor Vostiar
  • HETERODIMERIC HUMAN IgG1 POLYPEPTIDES WITH ISOELECTRIC POINT MODIFICATIONS
    Publication number: 20260152576
    Abstract: The invention relates generally to compositions and methods for purifying the desired species from a mixture of desired heterodimer and contaminating homodimer immunoglobulin variants by modifying the isoelectric point(s) of the individual chains.
    Type: Application
    Filed: November 13, 2025
    Publication date: June 4, 2026
    Inventors: Gregory L. Moore, Gregory Lazar
  • Heterodimeric human IgG1 polypeptides with isoelectric point modifications
    Patent number: 12617872
    Abstract: The invention relates generally to compositions and methods for purifying the desired species from a mixture of desired heterodimer and contaminating homodimer immunoglobulin variants by modifying the isoelectric point(s) of the individual chains.
    Type: Grant
    Filed: September 16, 2025
    Date of Patent: May 5, 2026
    Assignee: Xencor, Inc.
    Inventors: Gregory L. Moore, Gregory Lazar
  • HETERODIMERIC HUMAN IgG1 POLYPEPTIDES WITH ISOELECTRIC POINT MODIFICATIONS
    Publication number: 20260085132
    Abstract: The invention relates generally to compositions and methods for purifying the desired species from a mixture of desired heterodimer and contaminating homodimer immunoglobulin variants by modifying the isoelectric point(s) of the individual chains.
    Type: Application
    Filed: November 13, 2025
    Publication date: March 26, 2026
    Inventors: Gregory L. Moore, Gregory Lazar
  • ANTIGEN BINDING MOLECULES TO CD3 AND CD19
    Publication number: 20260070982
    Abstract: Disclosed herein are anti-CD3 antigen binding molecules, anti-CD19 antigen binding molecules, anti-CD19 and anti-CD3 bi-specific antigen binding molecules, and methods for the use thereof.
    Type: Application
    Filed: September 7, 2025
    Publication date: March 12, 2026
    Inventors: Matthew Bernett, Gregory L. Moore, Viralkumar Rameshkumar Davra, Katrina Bykova, Seung Y. Chu, Jing Qi, Su-Shin Hao, Kendra Avery, Jitendra Kanodia, Juan Diaz
  • HETERODIMERIC HUMAN IgG1 POLYPEPTIDES WITH ISOELECTRIC POINT MODIFICATIONS
    Publication number: 20260035485
    Abstract: The invention relates generally to compositions and methods for purifying the desired species from a mixture of desired heterodimer and contaminating homodimer immunoglobulin variants by modifying the isoelectric point(s) of the individual chains.
    Type: Application
    Filed: September 16, 2025
    Publication date: February 5, 2026
    Inventors: Gregory L. Moore, Gregory Lazar
  • HETERODIMERIC HUMAN IgG1 POLYPEPTIDES WITH ISOELECTRIC POINT MODIFICATIONS
    Publication number: 20260028429
    Abstract: The invention relates generally to compositions and methods for purifying the desired species from a mixture of desired heterodimer and contaminating homodimer immunoglobulin variants by modifying the isoelectric point(s) of the individual chains.
    Type: Application
    Filed: October 1, 2025
    Publication date: January 29, 2026
    Inventors: Gregory L. Moore, Gregory Lazar
  • Methods and compositions for inhibiting CD32B expressing cells in IGG4-related diseases
    Patent number: 12497457
    Abstract: The present invention relates to immunoglobulins that bind Fc?RIIb+ cells and coengage the antigen on the cell's surface and an Fc?RIIb on the cell's surface, methods for their generation, and methods for using the immunoglobulins.
    Type: Grant
    Filed: August 11, 2022
    Date of Patent: December 16, 2025
    Assignee: Xencor, Inc.
    Inventors: Seung Yup Chu, John R. Desjarlais, Sher Bahadur Karki, Gregory Alan Lazar, Gregory L. Moore, Igor Vostiar
  • Heterodimeric human IgG1 polypeptides with isoelectric point modifications
    Patent number: 12466897
    Abstract: The invention relates generally to compositions and methods for purifying the desired species from a mixture of desired heterodimer and contaminating homodimer immunoglobulin variants by modifying the isoelectric point(s) of the individual chains.
    Type: Grant
    Filed: March 21, 2025
    Date of Patent: November 11, 2025
    Assignee: Xencor, Inc.
    Inventors: Gregory L. Moore, Gregory Lazar
  • HETERODIMERIC HUMAN IgG1 POLYPEPTIDES WITH ISOELECTRIC POINT MODIFICATIONS
    Publication number: 20250230262
    Abstract: The invention relates generally to compositions and methods for purifying the desired species from a mixture of desired heterodimer and contaminating homodimer immunoglobulin variants by modifying the isoelectric point(s) of the individual chains.
    Type: Application
    Filed: March 21, 2025
    Publication date: July 17, 2025
    Inventors: Gregory L. Moore, Gregory Lazar
  • ANTI-CD20 x ANTI-CD28 COMBINATION THERAPIES
    Publication number: 20250122299
    Abstract: Provided herein are novel anti-CD20 x anti-CD28 antibodies and methods of using such antibodies for the treatment of B-cell malignancies. Subject anti-CD20 x anti-CD28 antibodies are capable of agonistically binding to CD28 costimulatory molecules on T cells and CD20 on tumor cells. Thus, such antibodies enhance anti-tumor activity at tumor sites. The subject antibodies provided herein are particularly useful in combination with other anti-cancer therapies (e.g., anti-CD3 x anti-CD20 x anti-CD79b antibodies) for the treatment of B-cell malignancies.
    Type: Application
    Filed: August 28, 2024
    Publication date: April 17, 2025
    Inventors: Gregory L. Moore, Michael Hedvat, Matthew Adam Dragovich, Lorena Fontan Gabas, Adam Zwolak, Ulrike Philippar, Pankaj Seth, Nele Vloemans, Ivo Cornelissen
  • Immunoprotection of Therapeutic Moieties Using Enhanced Fc Regions
    Publication number: 20250114440
    Abstract: The present application relates to therapeutic moieties displaying reduced immunogen response, particularly for therapeutic purposes.
    Type: Application
    Filed: May 10, 2024
    Publication date: April 10, 2025
    Inventors: John Desjarlais, Gregory L. Moore, Holly M. Horton
  • METHODS AND COMPOSITIONS FOR INHIBITING CD32B EXPRESSING CELLS IN IGG4-RELATED DISEASES
    Publication number: 20230227560
    Abstract: The present invention relates to immunoglobulins that bind Fc?RIIb+ cells and coengage the antigen on the cell's surface and an Fc?RIIb on the cell's surface, methods for their generation, and methods for using the immunoglobulins.
    Type: Application
    Filed: August 11, 2022
    Publication date: July 20, 2023
    Applicant: Xencor, Inc.
    Inventors: Seung Yup Chu, John R. Desjarlais, Sher Bahadur Karki, Gregory Alan Lazar, Gregory L. Moore, Igor Vostiar
  • Methods and compositions for inhibiting CD32B expressing cells
    Patent number: 11447552
    Abstract: The present invention relates to immunoglobulins that bind Fc?RIIb+ cells and coengage the antigen on the cell's surface and an Fc?RIIb on the cell's surface, methods for their generation, and methods for using the immunoglobulins.
    Type: Grant
    Filed: November 21, 2011
    Date of Patent: September 20, 2022
    Assignee: XENCOR, INC.
    Inventors: Seung Yup Chu, John R. Desjarlais, Sher Bahadur Karki, Gregory Alan Lazar, Gregory L. Moore, Igor Vostiar
  • Methods and compositions for inhibiting CD32B expressing cells
    Patent number: 11434295
    Abstract: The present invention relates to immunoglobulins that bind Fc?RIIb+ cells and coengage the antigen on the cell's surface and an Fc?RIIb on the cell's surface, methods for their generation, and methods for using the immunoglobulins.
    Type: Grant
    Filed: November 10, 2011
    Date of Patent: September 6, 2022
    Assignee: XENCOR, INC.
    Inventors: Seung Yup Chu, John R. Desjarlais, Sher Bahadur Karki, Gregory Alan Lazar, Gregory L. Moore, Igor Vostiar
  • METHODS AND COMPOSITIONS FOR INHIBITING CD32B EXPRESSING CELLS
    Publication number: 20210395363
    Abstract: The present invention relates to immunoglobulins that bind Fc?RIIb+ cells and coengage the antigen on the cell's surface and an Fc?RIIb on the cell's surface, methods for their generation, and methods for using the immunoglobulins.
    Type: Application
    Filed: August 30, 2021
    Publication date: December 23, 2021
    Applicant: XENCOR, INC.
    Inventors: Seung Yup Chu, John R. Desjarlais, Sher Bahadur Karki, Gregory Alan Lazar, Gregory L. Moore, Igor Vostiar
  • HETERODIMERIC HUMAN IgG1 POLYPEPTIDES WITH ISOELECTRIC POINT MODIFICATIONS
    Publication number: 20210284754
    Abstract: The invention relates generally to compositions and methods for purifying the desired species from a mixture of desired heterodimer and contaminating homodimer immunoglobulin variants by modifying the isoelectric point(s) of the individual chains.
    Type: Application
    Filed: October 12, 2020
    Publication date: September 16, 2021
    Inventors: Matthew J. Bernett, Gregory L. Moore, John Desjarlais, Rumana Rashid
  • Immunoprotection of Therapeutic Moieties Using Enhanced Fc Regions
    Publication number: 20210205426
    Abstract: The present application relates to therapeutic moieties displaying reduced immunogen response, particularly for therapeutic purposes.
    Type: Application
    Filed: August 10, 2020
    Publication date: July 8, 2021
    Inventors: John Desjarlais, Gregory L. Moore, Holly M. Horton
  • METHODS AND COMPOSITIONS FOR INHIBITING CD32B EXPRESSING CELLS
    Publication number: 20210009690
    Abstract: The present invention relates to immunoglobulins that bind Fc?RIIb+ cells and coengage the antigen on the cell's surface and an Fc?RIIb on the cell's surface, methods for their generation, and methods for using the immunoglobulins.
    Type: Application
    Filed: September 24, 2020
    Publication date: January 14, 2021
    Applicant: XENCOR, INC.
    Inventors: Seung Yup Chu, John R. Desjarlais, Sher Bahadur Karki, Gregory Alan Lazar, Gregory L. Moore, Igor Vostiar